Evelo Biosciences, Inc. (EVLO)
Evelo Biosciences, Inc.
620 Memorial Drive
5th Floor
Cambridge, MA 02139
United States
617 577 0300
https://www.evelobio.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 66
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Craig R. Jalbert CIRA | President, Secretary, Principal Executive, Financial and Accounting Officer & Director | N/D | N/D | 1962 |
| Dr. Chun Zhang Ph.D. | Chief Technical Operations & Quality Officer | N/D | N/D | N/D |
| Dr. Mark Bodmer Ph.D. | Chief Scientific Officer and President of Research & Development | 668.8k | N/D | 1958 |
| Ms. Jessica Cotrone | VP & Head of Communications | N/D | N/D | N/D |
| Ms. Leslie Wardwell-Scott Ph.D. | VP and Head of Corporate Development & Strategic Integration | N/D | N/D | N/D |
| Dr. Andrea Itano Ph.D. | Head of Research | N/D | N/D | N/D |
| Dr. Duncan McHale M.D., MBBS, Ph.D. | Chief Medical Officer | 661.97k | N/D | 1967 |
| Mr. Douglas Maslin | Senior Director & Immunology Clinical Lead | N/D | N/D | N/D |
Descripción
Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Gestión corporativa
La calificación ISS Governance QuickScore de Evelo Biosciences, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
